company background image
VLAP logo

Valneva BATS-CHIXE:VLAP Stock Report

Last Price

€1.92

Market Cap

€343.6m

7D

0%

1Y

n/a

Updated

10 Jan, 2025

Data

Company Financials +

VLAP Stock Overview

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details

VLAP fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Valneva SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for Valneva
Historical stock prices
Current Share Price€1.92
52 Week High€2.78
52 Week Low€1.87
Beta1.02
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-88.74%
5 Year Change-33.01%
Change since IPO-65.91%

Recent News & Updates

Recent updates

Shareholder Returns

VLAPGB BiotechsGB Market
7D0%-3.5%0.3%
1Yn/a-23.5%6.6%

Return vs Industry: Insufficient data to determine how VLAP performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how VLAP performed against the UK Market.

Price Volatility

Is VLAP's price volatile compared to industry and market?
VLAP volatility
VLAP Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: VLAP's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine VLAP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998700Thomas Lingelbachvalneva.com

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

Valneva SE Fundamentals Summary

How do Valneva's earnings and revenue compare to its market cap?
VLAP fundamental statistics
Market cap€343.57m
Earnings (TTM)-€7.42m
Revenue (TTM)€158.54m

2.2x

P/S Ratio

-46.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VLAP income statement (TTM)
Revenue€158.54m
Cost of Revenue€163.61m
Gross Profit-€5.08m
Other Expenses€2.34m
Earnings-€7.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 20, 2025

Earnings per share (EPS)-0.046
Gross Margin-3.20%
Net Profit Margin-4.68%
Debt/Equity Ratio79.4%

How did VLAP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 18:06
End of Day Share Price 2024/12/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Valneva SE is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stéphan DubosqArkeon Finance
Jean-Jacques Le FurBryan Garnier & Co
Bruno BulicBryan Garnier & Co